Corium sells off CDMO business for $400m
The company will split into two separate entities, one will focus on the development of neuroscience therapies and the other will become a standalone CDMO.
The company will split into two separate entities, one will focus on the development of neuroscience therapies and the other will become a standalone CDMO.
ObvioHealth has launched ObvioGo to reduce patient burden in decentralized clinical trials.
The long-running case relates to the change of formulation to its Levothyrox product, specifically the information the company provided when the product was altered.